PeptiDream Inc.
PPTDF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$874.26M
Close$
$1.38
79.8% downside
Current Fair Value
79.8% downsideOvervalued by 79.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $874.26 Million |
|---|---|
| Enterprise Value | $-6,392,730,477.00 |
| Earnings per Share | $-29.8 |
| Beta | 0.53 |
| Outstanding Shares | 128,567,724 |
Return
| Return on Equity | -7.55% |
|---|---|
| Return on Assets | -5.07% |
| Return on Invested Capital | -7.58% |
Valuation & Multiples
| P/E Ratio | -39.74 |
|---|---|
| PEG | -0.27 |
| Price to Sales | 0.05 |
| Price to Book Ratio | 0.02 |
| Enterprise Value to Revenue | 7.08 |
| Enterprise Value to EBIT | -28.18 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.34 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.02
Consensus analyst estimateRevenue Estimate
$34.90 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.04
Consensus analyst estimateRevenue Estimate
$32.12 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About PeptiDream Inc.
763 employees
CEO: Patrick Crawford Reid
PeptiDream Inc. functions as a biopharmaceutical enterprise, concentrating on the identification and progression of therapeutic compounds such as constrained peptides, small molecules, and peptide-drug conjugates. The company's unique pr...